DNDN and BIDU are being added to our top ten diversified stock list.
Dendreon shares are up 40% year to date. Shares got a further lift after a medicare panel endorsed its prostate cancer drug, Provenge.
Medicare sales would generate 400 million in 2011, 800 million in 2012 and up to $1.7 billion a year for Dendreon by 2014.
This is our biotech play for the diversified ten.
BIDU is our China play. The internet company is on an accelerating growth path.
W have previously announced TTM as our India auto play and PNRA as our Eatery sector play.
This list is for the long term.
| Find Winning Stocks Quickly with Research Wizard, a powerful desktop software program. Start with easy-to-use pre-loaded strategies, then develop your own. Backtest against years of historical data to see how your approach works in any market. Start a Free Trial Today >> |
|
No Stocks are Harder to Find, or More Worth the Effort. They have the greatest potential for quick gains, but they're also the most difficult to find and time correctly. Now Zacks has perfected a system for identifying and profiting from turnaround stocks just as they begin a powerful rebound. Learn more here >>. |
| Take advantage of quick short-term moves, and profit from price moves in any direction. Trade options under the direction of an expert guide. Try it now and get a 90-day unconditional money-back guarantee. 50% OFF for a limited time! Zacks Options Trader >> |
| Zacks Top Ten Stocks for 2011 are now available! This 10-stock portfolio is a well-balanced mix of aggressive and conservative, large and small cap, growth and value. Buy them. Hold them. Watch your gains add up |

Read MightyMo's blog in RSS


November 25, 2010
Edited: November 25, 2010
Share This